KBC Group NV reduced its stake in Stryker Corporation (NYSE:SYK - Free Report) by 14.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 265,410 shares of the medical technology company's stock after selling 45,453 shares during the quarter. KBC Group NV owned about 0.07% of Stryker worth $83,562,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. VanderPol Investments L.L.C. raised its stake in Stryker by 1.4% during the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company's stock worth $732,000 after buying an additional 28 shares during the last quarter. KCM Investment Advisors LLC lifted its stake in shares of Stryker by 1.5% in the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company's stock valued at $653,000 after purchasing an additional 28 shares during the period. Rossby Financial LCC boosted its position in shares of Stryker by 6.6% during the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company's stock valued at $159,000 after purchasing an additional 28 shares in the last quarter. Tcfg Wealth Management LLC grew its stake in Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company's stock worth $403,000 after purchasing an additional 29 shares during the period. Finally, West Michigan Advisors LLC lifted its stake in Stryker by 0.4% in the fourth quarter. West Michigan Advisors LLC now owns 7,468 shares of the medical technology company's stock valued at $2,631,000 after buying an additional 30 shares during the period. Institutional investors and hedge funds own 77.09% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages have recently commented on SYK. Needham & Company LLC reduced their price objective on shares of Stryker from $454.00 to $418.00 and set a "buy" rating for the company in a research report on Friday, May 1st. Citigroup reaffirmed a "buy" rating on shares of Stryker in a research note on Thursday. BMO Capital Markets began coverage on Stryker in a research note on Wednesday, July 8th. They issued an "outperform" rating and a $369.00 target price for the company. JPMorgan Chase & Co. dropped their price target on Stryker from $400.00 to $350.00 and set an "overweight" rating on the stock in a research note on Friday, July 31st. Finally, Royal Bank Of Canada reduced their price objective on Stryker from $435.00 to $420.00 and set an "outperform" rating for the company in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $386.28.
Read Our Latest Stock Report on SYK
Insider Buying and Selling
In other news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company's stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.60% of the stock is owned by corporate insiders.
Stryker Stock Performance
NYSE SYK opened at $338.80 on Friday. The company has a fifty day moving average price of $324.61 and a 200-day moving average price of $333.57. The firm has a market cap of $129.95 billion, a price-to-earnings ratio of 35.11, a PEG ratio of 2.16 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86.
Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion for the quarter, compared to analysts' expectations of $6.58 billion. During the same period in the previous year, the company earned $3.13 earnings per share. The firm's revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts predict that Stryker Corporation will post 15.02 EPS for the current fiscal year.
Stryker Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker's dividend payout ratio is presently 36.48%.
About Stryker
(
Free Report)
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
